Compare Booz Allen Hamilton Holding Corporation (BAH) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs Quest Diagnostics Inc — how do they compare? Booz Allen Hamilton Holding Corporation trades at $78.74 (market cap $9.45B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 2.8× Booz Allen Hamilton Holding Corporation's market cap, and Booz Allen Hamilton Holding Corporation pays the higher dividend (3%). Which is the better fit depends on your goals.
| BAH | DGX | |
|---|---|---|
Market Cap | $9.45B | $26.21B |
Sector | Industrials | Health |
52-Week High | $111.63 | $238.50 |
52-Week Low | $59.71 | $173.49 |
Enterprise Value | $13.07B | $31.97B |
Dividend Yield | 3% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $77.93, up 0.04% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 7.01% net margin and 68.11% ROE, while valuation ratios like P/E of 12.33 and P/S of 0.86 appear attractive. Recent Q2 2026 earnings beat estimates at $1.81 per share, and the company maintains consistent dividend payments, reflecting financial stability.
Outlook remains positive with analyst consensus price target of $84.67, though risks include high debt levels and civil revenue weakness. Growth in national security and AI investments offers upside, but investors should monitor leverage and sector-specific headwinds for balanced exposure.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
